-
Story
Q&A: Addressing unmet needs for people living with PNH, a rare and chronic blood disorder -
Story
When you think of the word ‘cancer’, what are the first words that spring to mind? -
Media ReleaseNovartis Entresto® granted expanded indication in chronic heart failure by FDA
-
Story
Breaking down barriers for patients with sickle cell disease -
Featured NewsSound Up for Lung Cancer
-
Media ReleaseAveXis Announces Alignment with FDA on Next Steps Toward a BLA Submission for AVXS-101 in SMA Type 1
-
Media ReleaseREGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular Atrophy
-
Media ReleaseAveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy
-
Media ReleaseAveXis Announces Proposed Public Offering of Common Stock
-
Media ReleaseAveXis Announces Pricing of Public Offering of Common Stock
-
Media ReleaseAveXis to Initiate Screening for Remaining Patients in Pivotal Trial of AVXS-101 for SMA Type 1 Following Review of Preliminary Data from First Three Patients
-
Media ReleaseAveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares